References
- Greaves MW, Philips CB. Mast cell disease and its pharmacologic regulation. J Invest Dermatol. 1978; 71: 94–4.
- Soter NA, Austen KF, Wasserman SI. Oral disodium chromoglycate in the treatment of systemic mastocytosis. N Engl J Med. 179; 301: 465–9.
- Shear NH, McLeod SM. Diffuse cutaneous mastocytosis: treatment with ketotifen and cimetidine. Clin Invest Med. 1983; 6 (suppl. 2): 36.
- Lewis RA. Mastocytosis. J Allergy Clin Immunol. 1984; 74: 755–65.
- Parker F, Oldland GF. The mastocytosis syndrome. In: Dermatology in General Medicine, ed. Fitzpratick TB et al. Mc GraW Hill Book Co 1972: 772–83.
- Odland GF, Parker F. Submicroscopic features of the degranulation of the human mast cell in localized mastocytosis. J Clin Invest. 1965; 44: 1081–4.
- Caplan RM. The natural course of urticaria pigmentosa. Arch Dermatol. 1863; 87: 146–57.
- Gagnon JH. Mastocytosis: unusual manifestations clinical and radiologic changes. Can Med Ass J. 1975; 112: 1332.
- Roberts LJ II, Sweetman BJ, Lewis RA, Folarin VF, Austin KF, Oats J A. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med. 1980; 303: 1400–4.
- Martin U, Baggiolini M. Dissociation between the anaphylactic and the antihistamine action of ketotifen. Arch Pharmacol 1981; 316: 186–9.
- Rademecker M. Inhibition of allergen-mediated histamine release from human mast cells by ketotifen and oxatomide. Respiration. 1981; 41: 45–55.
- Foreman JC, Garland LG. Chromoglycatc and other anti-allergic drugs: a possible mechanism of action. Br Med J 1976: 4: 820–1.
- Martin U, Romer D. Anti-anaphylactic properties of ketotifen in animal experiments. Triangle. 1978; 17: 1451–7.
- Ney U, Bretz U, Gradwohl P, Martin U. Further characterization of anti-anaphylactic action of ketotifen (Zaditen®). Allergol Immunopathol. 1980;8:479–82.